Sygnature Discovery and Pneumolabs have entered into a strategic alliance to provide a fully-integrated drug discovery service aimed at accelerating clients’ drug discovery programs into development. The alliance complements Sygnature’s existing partnership with Cyprotex Discovery, a center of excellence for in vitro ADME/toxicology, and Saretius, a preclinical experimental services company offering techniques in pain, metabolic and CNS disorders, inflammatory disease and in vivo pharmacokinetic...